Related Experiment Video
Updated: Jul 9, 2026
09:08
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Adenosine Pathway-Based Prognostic Signature for Predicting Clinical Outcomes and Immune Microenvironment
Akbar Ibrahimo1, Fidan Novruzova1
1Department of Oncology, Azerbaijan Medical University, Baku, Azerbaijan.
Journal of Clinical Practice and Research
|July 8, 2026
Summary
This study developed a new prognostic signature for epithelial ovarian cancer (EOC) using adenosynergic genes. This signature predicts patient survival and characterizes the tumor immune microenvironment, identifying VSIG4 as a potential therapeutic target.
Area of Science:
- Oncology
- Bioinformatics
- Immunology
Background:
- Epithelial ovarian cancer (EOC) poses significant challenges in prognosis and treatment.
- The tumor immune microenvironment plays a crucial role in EOC progression and response to therapy.
- Adenosine signaling is implicated in immune suppression within the tumor microenvironment.
Purpose of the Study:
- To develop and validate an adenosynergic prognostic signature for EOC.
- To characterize the tumor immune microenvironment based on adenosynergic signaling.
- To identify potential therapeutic targets within the adenosynergic pathway.
Main Methods:
- Retrospective bioinformatics analysis including Weighted Gene Co-expression Network Analysis (WGCNA) and LASSO Cox regression.
- Quantification of adenosine signaling activity using single-sample Gene Set Enrichment Analysis (ssGSEA).
- Validation of the prognostic signature using multiple datasets and in vitro experiments (qPCR, viability, migration, invasion assays).
Main Results:
- A nine-gene adenosynergic prognostic signature (5 risk, 4 protective genes) was developed, demonstrating robust predictive accuracy for overall survival.
- High-risk patients showed worse survival, reduced CD8+ T-cell and macrophage infiltration, indicating an immunosuppressive microenvironment.
- Experimental validation confirmed elevated adenosynergic gene expression and showed that VSIG4 silencing inhibited cancer cell proliferation, migration, and invasion.
Conclusions:
- A novel adenosynergic prognostic signature effectively stratifies EOC patient outcomes.
- The signature correlates with an immunosuppressive tumor microenvironment, offering insights into treatment resistance.
- VSIG4 is identified as a promising therapeutic target for EOC treatment.
